Phase I Clinical Study of a Multi-Kinase Inhibitor TG02 Capsule for the Treatment of Recurrent High-Grade Gliomas with Failed Temozolomide Treatment in Chinese Patients.
Saved in:
| Title: | Phase I Clinical Study of a Multi-Kinase Inhibitor TG02 Capsule for the Treatment of Recurrent High-Grade Gliomas with Failed Temozolomide Treatment in Chinese Patients. |
|---|---|
| Authors: | Guo CC; Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Yang QY; Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Xi SY; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.; Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China., Zhou J; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.; Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China., Zhou ZH; Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Cao X; Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Liao YX; Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Li BX; Lee's Pharmaceutical Holdings Limited, Hong Kong, Hong Kong, China., Dai XR; Lee's Pharmaceutical Holdings Limited, Hong Kong, Hong Kong, China., Wong M; Lee's Pharmaceutical Holdings Limited, Hong Kong, Hong Kong, China., Li YJ; Lee's Pharmaceutical Holdings Limited, Hong Kong, Hong Kong, China., Yu XH; Guangzhou Hankewei Pharmaceutical Technology Co. Ltd, Guangzhou, China., Chen ZP; Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China. |
| Source: | Chemotherapy [Chemotherapy] 2025; Vol. 70 (2), pp. 74-84. Date of Electronic Publication: 2024 Nov 18. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Karger Country of Publication: Switzerland NLM ID: 0144731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9794 (Electronic) Linking ISSN: 00093157 NLM ISO Abbreviation: Chemotherapy Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1421-9794 |
|---|---|
| DOI: | 10.1159/000542365 |
